GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 50 Health Care Professionals (HCPs) Your Company works with HCPs to understand patient needs and to ensure the HCPs understand the science behind GSK’s medicines. How your Company engages with HCPs — Scientific dialogue to increase understanding of disease management and patient experience — Providing high quality, balanced information about our medicines and vaccines What matters — Access to product and scientific information — Responsible sales and marketing practices — Safety, efficacy and differentiated innovation What your Company is doing — Increasing the use of digital channels to deliver a more personalised and effective sharing of information to HCPs Government and regulators Your Company works with the government and regulators to advocate for policies which encourage innovation, promote efficient management of healthcare spending, and give patients the support they need. How your Company engages with governments and regulators — Meeting with regulatory bodies throughout the product introduction process to ensure high quality and safe new products — Engaging with government health agencies to demonstrate the value of our products — Working with the government to build a strong operating environment for healthcare What matters — Environment which values innovation and drives investment in healthcare — Pricing of medicines — Public health threats — Scientific funding and collaboration What your Company is doing — Working with policy-makers to support an operating environment that remains competitive for investment, enables mobility of scientific talent, and accelerates the uptake of innovative medicines — Actively focusing on government proposals for healthcare reform — Partnering with authorities to ensure support for global innovation, including swift regulatory approval for our pipeline products NGOs and multilateral organisations Your Company works with non-governmental organisations (NGOs) and multilateral organisations to improve access to healthcare and provide educational support through its corporate social responsibility (CSR) initiatives. How your Company engages with NGOs and multilateral organisations — Working with NGOs and partners to implement CSR initiatives in communities — Partnering with multilateral organisations like the World Health Organization (WHO) to address the public health issue of lymphatic filariasis in India What matters — Achieving the UN Sustainable Development Goals (SDGs) — Achieving World Health Organization (WHO) targets for specific disease areas and providing access to medicine What your Company is doing — Leveraging CSR programmes to deliver more impact for communities and vulnerable sections — Focusing on unique value-addition as a global health partner to develop products in the domain where we have scientific expertise, through our global health programmes Suppliers Your Company works with multiple suppliers, large and small, who provide goods and services that support your Company in delivering a reliable supply of high quality, safe products for patients. How your Company engages with suppliers — Regular, direct engagement between business owner and supplier to ensure they support your Company’s strategies and targets — Engage with suppliers through your Company’s Third Party Oversight (TPO) programme, by conducting in-depth audits and by adding additional dimensions related to Risk identification and mitigation programmes — Participate in cross-industry forums such as the Organisation of Pharmaceutical Producers of India (OPPI) and Convention of Pharmaceutical Ingredients (CPhI) to improve supply chain sustainability What matters — Prompt adherence to payment terms, especially for small and micro category MSME suppliers — Understanding of GSK standards, policies and procedures to ensure compliance — Opportunities to innovate and grow relationships with suppliers What your Company is doing — Updating and adherence to prescribed payment practices to ensure that MSME suppliers benefit from preferential payment terms — Conducting business with suppliers who share your Company’s values and maintain high quality and ethical standards to ensure the security of supply — Engaging with suppliers to develop improvement plans and track progress when areas for improvement are identified Annexure ‘B’ Business Responsibility (BR) Report